Wu, 2025 - Google Patents
Assessing the safety and efficacy of PODO83 and PODO447-ADC as cancer therapeuticsWu, 2025
View PDF- Document ID
- 7569810801992220976
- Author
- Wu J
- Publication year
External Links
Snippet
Although advances in the field have improved understanding of cancer diagnosis and treatment, the disease still remains one of the leading causes of death globally. While some cancers are susceptible to conventional treatment options, others relapse or metastasize …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11459388B2 (en) | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance | |
| ES2822228T3 (en) | Compositions and methods for inducing phagocytosis of MHC class I positive cells and counteracting resistance to anti-CD47 / SIRPA | |
| US20210277115A1 (en) | Targeted therapy for small cell lung cancer | |
| Yang et al. | Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma | |
| UA120753C2 (en) | Anti-cd3 antibodies and methods of use | |
| US20130089872A1 (en) | Anti-human trop-2 antibody having anti-tumor activity in vivo | |
| UA120247C2 (en) | Anti-ceacam5 antibodies and uses thereof | |
| UA123428C2 (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| KR20170008202A (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
| UA113838C2 (en) | ANTIBODY Binding Mesothelin and Immunoconjugate | |
| UA119036C2 (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| UA126561C2 (en) | Anti-c5 antibodies and methods of use | |
| ES2355503T3 (en) | METHODS TO REGULATE CANCER. | |
| WO2024149232A1 (en) | Nanoantibody b12 targeting ceacam5 and use of nanoantibody b12 | |
| ES2476798T3 (en) | New glycosylated peptide target in neoplastic cells | |
| Guo et al. | FUT2-dependent fucosylation of LAMP1 promotes the apoptosis of colorectal cancer cells by regulating the autophagy-lysosomal pathway | |
| Wu | Assessing the safety and efficacy of PODO83 and PODO447-ADC as cancer therapeutics | |
| Hagerty et al. | Novel humanized mesothelin-expressing genetically engineered mouse models underscore challenges in delivery of complex therapeutics to pancreatic cancers | |
| US20200061216A1 (en) | Tumor specific antibody conjugates and uses therefor | |
| WO2024230090A1 (en) | Use of sialyltransferase inhibitor in preparing medicament for neutralizing acidic tumor microenvironment | |
| JP2025513747A (en) | Novel mcl-1 inhibitors and combinations of mcl-1 and bcl-2 inhibitors such as bh3 mimetics | |
| HK1215390A1 (en) | Model of colorectal cancer | |
| You et al. | Establishment and characterization of two human cutaneous angiosarcoma cell lines, KU‐CAS3 and KU‐CAS5 | |
| WO2021209670A1 (en) | Therapeutic treatment for t-cell acute lymphoblastic leukemias using a monoclonal antibody against the pre-t cell receptor | |
| JP2022515131A (en) | Phosphorylation dicer antibody and how to use it |